This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

LifeSci Advisors Announces Investment Opinion On Transition Therapeutics, Inc.

LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the life sciences sector, today announced that it has initiated coverage of Transition Therapeutics, Inc. ("Transition") (TSX: TTH) (NASDAQ: TTHI), a biopharmaceutical company, developing novel therapeutics for disease indications with large markets. Transition's lead products include:

  • ELND005: small molecule drug to enter Phase 3 for the treatment of Alzheimer's disease
  • TT401/TT402: long-acting GLP-1 dual agonists for type 2 diabetes that provide glycemic control, weight management, improved lipid profile and better GI tolerability
  • TT301/TT302: novel orally bioavailable aminopyridizines for rheumatoid arthritis, that inhibit multiple pro-inflammatory cytokines and chemokines

“Transition’s strong record of executing against their business model is quite impressive,” said Andrew I. McDonald, Ph.D., Managing Director at LifeSci Advisors. “They have a strong cash position, no debt, and their lead drug, ELND005, is poised to enter Phase 3 for Alzheimer’s disease in partnership with Elan, who are responsible for all Phase 3 costs, leaving only upside potential for Transition. With ELND005’s disease-modifying mechanism and oral dosing advantage, it is positioned to compete successfully in the burgeoning Alzheimer’s disease space, a market with potential to exceed $10 Billion in annual worldwide sales. Transition’s earlier stage pipeline includes diabetes compounds TT401/402 which have a highly compelling profile and TT301/TT302, which are positioned for success in rheumatoid arthritis as oral successors to the current biologic therapies.”

In a 53-page Initiation Report by LifeSci Advisors, the preclinical and clinical achievements of ELND005 to date are presented, as is a detailed analysis favoring use of the drug in early stage Alzheimer’s patients. The safety and pharmacokinetics of ELND005 has been evaluated in a total of nine Phase 1 studies in 161 healthy volunteers, including healthy elderly subjects. A recently completed Phase 2 study called AD201 was a randomized, double-blind, placebo-controlled, dose-ranging study for ELND005 in patients with mild to moderate Alzheimer’s disease. For AD201, mild to moderate patients, aged 50-85 years were randomized, and an open label extension of the study called AD251 is ongoing. The report also examines the rapidly changing landscape for drug development in the growing Alzheimer’s disease space, including the ongoing paradigm shift within the field regarding increasing use of biomarkers and the evolving perspective on selection of inclusion criteria and endpoints for clinical studies. Also emphasized is the importance of providing disease modifying therapy to patients at earlier stages of the disease, where the potential for patient benefit is greatest.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,135.72 +38.82 0.21%
S&P 500 2,101.04 +2.51 0.12%
NASDAQ 4,982.8090 +15.6680 0.32%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs